A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT02533453

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02533453
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02533453. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01-28 (actual); primary completion 2016-12-07 (actual). Results posted on 2019-05-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
Acronym
Bydureon
Condition
Type 2 Diabetes Mellitus
Intervention (Biological)
Bydureon
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02533453
Content hash
3e23d348d5d03d132e709964a83df05f69e342cf39335e56cf3744c562ac33f4